{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.89","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"31","value":"17.4"},{"groupId":"OG001","lowerLimit":"12","upperLimit":"36","value":"21.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Responses assessed using CT scans or magnetic resonance imaging according to standard RECIST 1.1 criteria in order to assess disease progression. CR: Disappearance all target lesions; any pathological lymph nodes reduction in short axis to \\< 10 mm (\\< 1 cm). PR: \\> 30% decrease in sum diameters of target lesions. PD: \\> 20% increase in sum diameters lesions. (Note: appearance of one or \\> new lesions considered progressions). SD: Neither shrinkage qualify for PR nor increase for PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants enrolled into Arm I received single agent Nivolumab.","id":"OG000","title":"Part B Arm I (Nivolumab)"},{"description":"Participants enrolled into Arm II received combination Nivolumab plus Ipilimumab.","id":"OG001","title":"Part B Arm II (Nivolumab, Ipilimumab"}],"paramType":"NUMBER","populationDescription":"Of the 100 participants enrolled into Part B of the study, 88 participants were evaluable for response per RECIST 1.1. The remaining 12 participants were not evaluable for treatment response.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Response Rate (Part B)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}